Concepedia

Author

Alexei Degterev

Tufts UniversityORCID

Also Known As

A Degterev, A. Degterev, A. I. Degterev, Alexandre R. Gingras, Alexei Degterev, Alexei I. Degterev, Degterev, A., Degterev, Alexei

121

Publications

16.5K

Citations

50

H-Index

118

Concepts

All Affiliations

Tufts UniversityHarvard UniversityMassachusetts General HospitalBrigham and Women's HospitalFox Chase Cancer Center
AD

About

Alexei Degterev is an author at Tufts University specializing in medicine, pharmacology, and cell death.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

34

9.7K

2

Natural Sciences

7

7

1.6K

3

Engineering

5

5

226

4

Health Sciences

2

2

329

5

Social Sciences

2

2

52

Alexei Degterev

×

67

Publications

12.8K

Citations

41

H-Index

YearCitations

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

Alexei Degterev, Zhihong Huang, Michael Boyce,

Nature Chemical Biology

2005

3K

Identification of RIP1 kinase as a specific cellular target of necrostatins

Alexei Degterev, Junichi Hitomi, Megan Germscheid,

Nature Chemical Biology

2008

2K

Identification of a Molecular Signaling Network that Regulates a Cellular Necrotic Cell Death Pathway

Junichi Hitomi, Dana E. Christofferson, Aylwin Ng,

Cell

2008

970

An atlas of substrate specificities for the human serine/threonine kinome

Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman,

Nature

2023

621

Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G

Nathan J. Moerke, Hüseyin Aktaş, Han Chen,

Cell

2007

565

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

Alexei Degterev, Alexey A. Lugovskoy, Michael H. Cardone,

Nature Cell Biology

2001

546

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

Nozomi Takahashi, Linde Duprez, Sasker Grootjans,

Cell Death and Disease

2012

438

Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases

Roshan J. Thapa, Shoko Nogusa, Peirong Chen,

Proceedings of the National Academy of Sciences

2013

342

RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4

Malek Najjar, Danish Saleh, Matija Zelic,

Immunity

2016

282

Necrostatin-1 Reduces Histopathology and Improves Functional Outcome after Controlled Cortical Impact in Mice

Zerong You, Sean I. Savitz, Jinsheng Yang,

Journal of Cerebral Blood Flow & Metabolism

2008

266

Page 1